Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
KETOPROFEN
SANOFI-AVENTIS CANADA INC
M01AE03
KETOPROFEN
100MG
SUPPOSITORY
KETOPROFEN 100MG
RECTAL
30
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0110497002; AHFS:
APPROVED
2006-05-25
PRODUCT MONOGRAPH RHODIS ® (Ketoprofen) 100 mg Suppositories RHODIS ® EC 50 mg, 100 mg Enteric-Coated Tablets Anti-Inflammatory Analgesic Agent sanofi-aventis Canada Inc. Date of Preparation: 2150 St. Elzear Blvd. West June 2, 2006 Laval, Quebec H7L 4A8 Submission Control No. 106123 s-a Version 1.0 dated 2 NAME OF DRUG RHODIS ® (Ketoprofen) 100 mg Suppositories RHODIS ® EC 50 mg, 100 mg Enteric-Coated Tablets THERAPEUTIC CLASSIFICATION Anti-inflammatory analgesic agent. ACTIONS AND CLINICAL PHARMACOLOGY Animal pharmacological studies have shown that ketoprofen is a non-steroidal anti-inflammatory drug that possesses anti-inflammatory, analgesic and antipyretic properties. The anti-inflammatory action is not mediated through the pituitary adrenal axis. Its therapeutic effectiveness has been demonstrated by a reduction in joint swelling, pain and duration of morning stiffness, and by increased grip strength and an improvement in functional capacity. Clinical trials in rheumatoid arthritis have shown that the anti-arthritic activity of RHODIS (ketoprofen) 200 mg/day was similar to that of acetylsalicylic acid 3.6 g/day. RHODIS ® 200 mg daily induced less gastrointestinal bleeding than acetylsalicylic acid 4 g daily. The effectiveness of RHODIS ® as a general purpose analgesic has been studied in standard pain models which have shown the effectiveness of doses of 25 to 150 mg. Doses of 25 mg were superior to placebo. Larger doses than 25 mg generally could not be shown significantly more effective but there was a tendency toward faster onset and greater duration of action with 50 mg and, in the case of dysmenorrhea, a significantly greater effect overall with 75 mg. Doses greater than 50 to 75 mg did not have increased analgesic effect. Pharmacokinetics properties: In man, RHODIS ® (ketoprofen) is rapidly and almost completely absorbed from the gastrointestinal tract. Maximum plasma levels are reached within 1/2 to 2 hours after administration of capsules or suppositories; however, peak plasma levels are delay Baca dokumen lengkapnya